Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bioequivalence of Fulvestrant Injection vs Faslodex in Healthy Post-menopausal Women
NCT02795039Phase 1Completed
- Sponsor
- Fresenius Kabi
- Start
- Jun 2016
- Primary completion
- Mar 2017
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of fulvestrant in breast cancer (2 arms), sponsored by Fresenius Kabi. Primary endpoints: Maximum observed plasma concentration and Area under the plasma concentration versus time curve (AUC0-238d). Started Jun 2016; status: completed.
02
Drugs
fulvestrant
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT02795039.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02795039.